Thankfully, for $NBIO shareholders, PTB recently completed its landmark Phase I trial. The company is now working with the FDA to quickly line up Phase II research, where the rubber really meets the road.
As noted in its most recent release, its Phase I clinical trial evaluating safety and tolerance for PTB as a treatment for Primary and Metastatic Brain Cancers has been completed, and Nascent pledges to continue to collect and evaluate the Clinical data from the Phase I trial while readying its submission to the U.S. FDA for Phase II consideration.
News 
Market Data 
Discover 
AI
